Antiproliferative effects of TSA, PXD‑101 and MS‑275 in A2780 and MCF7 cells: Acetylated histone H4 and acetylated tubulin as markers for HDACi potency and selectivity

Androutsopoulos,Vasilis P.; Spandidos,Demetrios A.

doi:10.3892/or.2017.6015

Antiproliferative effects of TSA, PXD‑101 and MS‑275 in A2780 and MCF7 cells: Acetylated histone H4 and acetylated tubulin as markers for HDACi potency and selectivity

Authors:
- Vasilis P. Androutsopoulos
- Demetrios A. Spandidos
View Affiliations

Affiliations: Laboratory of Clinical Virology, Medical School, University of Crete, Heraklion, Voutes 71003, Greece
Published online on: October 6, 2017 https://doi.org/10.3892/or.2017.6015
Pages: 3412-3418
Copyright: © Androutsopoulos et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inhibition of histone deacetylase enzymes (HDACs) has been well documented as an attractive target for the development of chemotherapeutic drugs. The present study investigated the effects of two prototype hydroxamic acid HDAC inhibitors, namely Trichostatin A (TSA) and Belinostat (PXD‑101) and the benzamide Entinostat (MS‑275) in A2780 ovarian carcinoma and MCF7 breast adenocarcinoma cells. The three HDACi inhibited the proliferation of A2780 and MCF7 cells at comparable levels, below the µM range. Enzyme inhibition assays in a cell‑free system showed that TSA was the most potent inhibitor of total HDAC enzyme activity followed by PXD‑101 and MS‑275. Incubation of A2780 and MCF7 cells with the hydroxamates TSA and PXD‑101 for 24 h resulted in a dramatic increase of acetylated tubulin induction (up to 30‑fold for TSA). In contrast to acetylated tubulin, western blot analysis and flow cytometry indicated that the induction of acetylated histone H4 was considerably smaller. The benzamide MS‑275 exhibited nearly a 2‑fold induction of acetylated histone H4 and an even smaller induction of acetylated tubulin in A2780 and MCF7 cells. Taken together, these data suggest that although the three HDACi were equipotent in inhibiting proliferation of MCF7 and A2780 cells, only the benzamide MS‑275 did not induce acetylated tubulin expression, a marker of class IIb HDACs.

View Figures

View References

1	Kristensen LS, Nielsen HM and Hansen LL: Epigenetics and cancer treatment. Eur J Pharmacol. 625:131–142. 2009. View Article : Google Scholar : PubMed/NCBI
2	Witt O, Deubzer HE, Milde T and Oehme I: HDAC family: What are the cancer relevant targets? Cancer Lett. 277:8–21. 2009. View Article : Google Scholar : PubMed/NCBI
3	Gray SG and Ekström TJ: The human histone deacetylase family. Exp Cell Res. 262:75–83. 2001. View Article : Google Scholar : PubMed/NCBI
4	Mehnert JM and Kelly WK: Histone deacetylase inhibitors: Biology and mechanism of action. Cancer J. 13:23–29. 2007. View Article : Google Scholar : PubMed/NCBI
5	Emanuele S, Lauricella M and Tesoriere G: Histone deacetylase inhibitors: Apoptotic effects and clinical implications (Review). Int J Oncol. 33:637–646. 2008.(Review). PubMed/NCBI
6	Glaser KB: HDAC inhibitors: Clinical update and mechanism-based potential. Biochem Pharmacol. 74:659–671. 2007. View Article : Google Scholar : PubMed/NCBI
7	Wilcox RA: Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 91:151–165. 2016. View Article : Google Scholar : PubMed/NCBI
8	Hess-Stumpp H, Bracker TU, Henderson D and Politz O: MS-275, a potent orally available inhibitor of histone deacetylases-the development of an anticancer agent. Int J Biochem Cell Biol. 39:1388–1405. 2007. View Article : Google Scholar : PubMed/NCBI
9	Tan J, Cang S, Ma Y, Petrillo RL and Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 3:52010. View Article : Google Scholar : PubMed/NCBI
10	O'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, Hess G, Jurczak W, Knoblauch P, Chawla S, et al: Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 33:2492–2499. 2015. View Article : Google Scholar : PubMed/NCBI
11	Batlevi CL, Kasamon Y, Bociek RG, Lee P, Gore L, Copeland A, Sorensen R, Ordentlich P, Cruickshank S, Kunkel L, et al: ENGAGE-501: Phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma. Haematologica. 101:968–975. 2016. View Article : Google Scholar : PubMed/NCBI
12	Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, et al: Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 409:581–589. 2008. View Article : Google Scholar : PubMed/NCBI
13	Boissinot M, Inman M, Hempshall A, James SR, Gill JH, Selby P, Bowen DT, Grigg R and Cockerill PN: Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192. Leuk Res. 36:1304–1310. 2012. View Article : Google Scholar : PubMed/NCBI
14	Ronzoni S, Faretta M, Ballarini M, Pelicci P and Minucci S: New method to detect histone acetylation levels by flow cytometry. Cytometry A. 66:52–61. 2005. View Article : Google Scholar : PubMed/NCBI
15	Davies GF, Ross AR, Arnason TG, Juurlink BH and Harkness TA: Troglitazone inhibits histone deacetylase activity in breast cancer cells. Cancer Lett. 288:236–250. 2010. View Article : Google Scholar : PubMed/NCBI
16	Takai N and Narahara H, Takai N and Narahara H: Human endometrial and ovarian cancer cells: Histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. Curr Med Chem. 14:2548–2553. 2007. View Article : Google Scholar : PubMed/NCBI
17	Marquard L, Petersen KD, Persson M, Hoff KD, Jensen PB and Sehested M: Monitoring the effect of belinostat in solid tumors by H4 acetylation. APMIS. 116:382–392. 2008. View Article : Google Scholar : PubMed/NCBI
18	Rigby L, Muscat A, Ashley D and Algar E: Methods for the analysis of histone H3 and H4 acetylation in blood. Epigenetics. 7:875–882. 2012. View Article : Google Scholar : PubMed/NCBI
19	Duong V, Bret C, Altucci L, Mai A, Duraffourd C, Loubersac J, Harmand PO, Bonnet S, Valente S, Maudelonde T, et al: Specific activity of class II histone deacetylases in human breast cancer cells. Mol Cancer Res. 6:1908–1919. 2008. View Article : Google Scholar : PubMed/NCBI
20	Dejligbjerg M, Grauslund M, Litman T, Collins L, Qian X, Jeffers M, Lichenstein H, Jensen PB and Sehested M: Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells. Mol Cancer. 7:702008. View Article : Google Scholar : PubMed/NCBI
21	Baradari V, Huether A, Höpfner M, Schuppan D and Scherübl H: Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. Endocr Relat Cancer. 13:1237–1250. 2006. View Article : Google Scholar : PubMed/NCBI
22	Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M, Lichenstein HS and Jeffers M: Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther. 5:2086–2095. 2006. View Article : Google Scholar : PubMed/NCBI
23	Arts J, Angibaud P, Mariën A, Floren W, Janssens B, King P, van Dun J, Janssen L, Geerts T, Tuman RW, et al: R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer. 97:1344–1353. 2007. View Article : Google Scholar : PubMed/NCBI
24	Strait KA, Dabbas B, Hammond EH, Warnick CT, Iistrup SJ and Ford CD: Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol Cancer Ther. 1:1181–1190. 2002.PubMed/NCBI
25	Strait KA, Warnick CT, Ford CD, Dabbas B, Hammond EH and Ilstrup SJ: Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad. Mol Cancer Ther. 4:603–611. 2005. View Article : Google Scholar : PubMed/NCBI
26	Liu T, Kuljaca S, Tee A and Marshall GM: Histone deacetylase inhibitors: Multifunctional anticancer agents. Cancer Treat Rev. 32:157–165. 2006. View Article : Google Scholar : PubMed/NCBI
27	Hong S, Derfoul A, Pereira-Mouries L and Hall DJ: A novel domain in histone deacetylase 1 and 2 mediates repression of cartilage-specific genes in human chondrocytes. FASEB J. 23:3539–3552. 2009. View Article : Google Scholar : PubMed/NCBI
28	Chandrasekaran S, Peterson RE, Mani SK, Addy B, Buchholz AL, Xu L, Thiyagarajan T, Kasiganesan H, Kern CB and Menick DR: Histone deacetylases facilitate sodium/calcium exchanger up-regulation in adult cardiomyocytes. FASEB J. 23:3851–3864. 2009. View Article : Google Scholar : PubMed/NCBI